argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

NEXT STORY
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
PREV STORY
Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Woven Science’s El Puente Releases Its Policy Paper on Indigenous Reciprocity & Corporate Social Responsibility

author_avatar
NASDAQ Market News

Global Interventional Radiology Products (Stents, Catheters, IVC Filter, Accessories) Market 2017 – Forecast to 2021 for the $8 Billion Market

Dublin, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition ...

author_avatar
NASDAQ Market News

Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor

author_avatar
NASDAQ Market News